Vignette study for Treatment Selection in Patients with Non-small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations (LOGIK-0903)

Vignette study for Treatment Selection in Patients with Non-small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations (LOGIK-0903) - Vignette Study for Treatment Selection in Patients with Non-small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations (LOGIK-0903)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003523

Enrollment

300

Registered

2010-04-22

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small-Cell Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who are proven non-small cell lung cancer harboring EGFR mutations, acceptable for drug treatment and with written informed consent for this study 2) Doctors or Medical staff working on lung cancer treatment with written informed consent for this study

Exclusion criteria

Exclusion criteria: 1) Patients who have previously treated with standard platinum doublet chemotherapy, single chemotherapy for elderly or EGFR-TKI

Design outcomes

Primary

Measure	Time frame
To investigate the reason for treatment selection by patients, physician or medical staff.	—

Secondary

Measure	Time frame
To investigate any correlation between patient treatment choice and FACT-L or HADS To explore any gap in treatment choice between patients and physicians or medical staff.	—

Countries

Japan

Contacts

Public ContactJiichiro Sasaki

Faculty of Medicine, Kitasato University Department of Respiratory Medicine

saji@med.kitasato-u.ac.jp042-778-6412

Outcome results